好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparing Deep Learning and Classical Machine Learning Methods For Differentiating Primary CNS Lymphomas From Gliomas – A Systematic Review
Neuro-oncology
P14 - Poster Session 14 (11:45 AM-12:45 PM)
4-004
To compare and synthesize the findings on the application of different Deep Learning (DL)- versus classical ML- (cML) based models in differentiating Primary CNS Lymphomas (PCNSL) from gliomas.
Differentiating gliomas from PCNSL represents a diagnostic challenge with important therapeutic ramifications. MR-imaging combined with ML has shown promising results in differentiating these tumors non-invasively. 
A systematic search of literature was performed in February 2021 on Ovid Embase, Ovid MEDLINE, Cochrane trials, and Web of Science – Core Collection. The search strategy included keywords and controlled vocabulary including the terms: gliomas, artificial intelligence, machine learning, deep learning, and related terms. Publications were reviewed and screened by four different reviewers in accordance with TRIPOD.

The literature search yielded 11,727 studies and 1,141 underwent full-text review. Data was extracted from 23 publications. Nineteen studies used cML only, two DL only, and two both. Analyzed databases had an average size of 99 patients/study. 26.1% of publications reported external validation. The most tested ML and deep learning algorithms were Support Vector Machines (SVM) and Multilayer Perceptron Networks (MLP), respectively. For cML a Logistical Regression model achieved the highest AUC (0.961) in external validation, while an MLP achieved the highest for DL (0.947).  Both were trained on conventional radiomic features from routine and DWI sequences. End-to-end classifiers like Convolutional Neural Networks (CNN) achieved lower AUC in external validation (0.49 and 0.89).

AI-based methods for differentiating gliomas and PCNSL have been reported and show that ML models can achieve AUC > 0.94 in external validation. Classifiers using preextracted handcrafted features performed better than end-to-end deep classifiers. CNNs, when not regularized properly, are prone to overfitting and benefit from large datasets. With few studies using DL algorithms further research into novel DL-based approaches is recommended. Additionally, most studies lack large datasets and external validation, increasing the risk of overfitting. 

Authors/Disclosures
Irene Dixe de Oliveira Santo, MD (Yale New Haven Hospital)
PRESENTER
Dr. Dixe de Oliveira Santo has nothing to disclose.
Gabriel I. Cassinelli Petersen (University of Tübingen) Mr. Cassinelli Petersen has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Sara Merkaj (Yale School of Medicine) Mrs. Merkaj has nothing to disclose.
Ryan C. Bahar (Yale School of Medicine) Mr. Bahar has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Ajay Malhotra Ajay Malhotra has nothing to disclose.
Antonio M. Omuro, MD, FAAN (Stanford University) Dr. Omuro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Therapeutics. Dr. Omuro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Telix. Dr. Omuro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Curevac. The institution of Dr. Omuro has received research support from NIH. The institution of Dr. Omuro has received research support from Arcus Biosciences. The institution of Dr. Omuro has received research support from Denovo Biopharma. The institution of Dr. Omuro has received research support from Ono Pharmaceutical. The institution of Dr. Omuro has received research support from Servier. The institution of Dr. Omuro has received research support from Nanopharmaceuticals. The institution of Dr. Omuro has received research support from Denovo.
Mariam Aboian, MD, PhD (Yale University) Dr. Aboian has a non-compensated relationship as a Principal Investigator with Visage Imaging that is relevant to AAN interests or activities.